Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CycloSam Dose Finding Study in Osteosarcoma and Bone Metastases
NCT03612466Phase 1Withdrawn
- Sponsor
- Albert Einstein College of Medicine
- Start
- Aug 2022
- Primary completion
- Jan 2023
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of samarium-153-dotmp in osteosarcoma (OS) and bone metastases, sponsored by Albert Einstein College of Medicine. Primary endpoint: Maximally Tolerated Dose at 70 days. Planned start Aug 2022; status: withdrawn.
02
Drugs
samarium-153-dotmp
03
Conditions
osteosarcoma (OS)bone metastases
Beyond the preview
Go deeper on NCT03612466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03612466.